Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
November 8, 2017 7:00 AM EST260+ Fabry Patients on Reimbursed Galafold (Migalastat) and On Target to Reach 300 Patients by Year-End 2017
U.S. NDA Submission for Migalastat Planned in 4Q17
Pompe Retrospective and Prospective Data Collection Studies Initiated
Additional Pompe Clinical Data to be Presented at WORLDSymposium in February 2018
CRANBURY, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of... More
